secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
CIK:        0001335105
Form:       8-K
Filed at:   2025-02-21T23:59:59+00:00
Accession:  0001493152-25-007865
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Lixte Biotechnology fails Nasdaq equity minimum; plans appeal to avoid delisting
--------------------------------------------------------------------------------

- Failed to meet Nasdaq's $2.5M stockholders' equity requirement by Feb 18, 2025 extension deadline.
- Received Staff determination letter on Feb 19, 2025; intends to appeal and request a hearing.
- Appeal will automatically stay delisting of common stock (LIXT) and warrants (LIXTW) pending Panel decision.
- Nasdaq Hearings Panel may grant additional extension until Aug 18, 2025 to regain compliance.
- Company had previously submitted a compliance plan in Oct 2024 after initial Aug 2024 deficiency notice.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1335105/000149315225007865/0001493152-25-007865-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1335105/000149315225007865/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-007865

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer